&w=3840&q=100)
Stocks to Watch today, July 9: Ola, Tata Motors, Dixon Tech
At 7:19 AM, GIFT Nifty futures were trading at 25 points lower at 25,578, signalling a subdued start. Global markets also remained flat with the S&P 500 index ending the session at 6,225.52. The Dow Jones Industrial Average plummeted over 165 points or 0.37 per cent, concluding at 44,240.76.
In the Asia-Pacific region as well, the cautious sentiment prevailed with Japan's Nikkei quoting 39,615.09, down by 72 points or 0.18 per cent. The Hang Seng index was down by 233 points or nearly 1 per cent, at 23,915.37.
On the global front, Trump has once again dropped a bomb for the pharma sector, warning that the industry could witness a triple-digit tariff rate. 'They're going to be tariffed at a very, very high rate, like 200 percent,' Trump reportedly said.
Here is a list of stocks to watch today:
Union Bank of India: In its latest quarterly update, the banking firm reported a 5.01 per cent year-on-year (Y-o-Y) growth in its total business at ₹22.14 lakh crore for the first quarter of FY26. Domestic deposits stood at ₹12.40 lakh crore, up 3.62 per cent Y-o-Y, but down 2.54 per cent Q-o-Q. The Bank's total domestic RAM (Retail, Agriculture and MSME) advances surged 10.31 per cent Y-o-Y during the same period. Within this segment, domestic retail advances stood out with an impressive growth of 25.60 per cent Y-o-Y.
Ola Electric: The EV player launched a mass roll-out of MoveOS 5 for its S1 scooters and Roadster X motorcycles. As per the company release, the new update is aimed at providing enhanced performance, better reliability and increased range. As per the company release, the new update also includes advanced battery management features to provide improved battery performance and health.
Tata Motors: In Q1FY26, the Tata group firm reported global wholesales (including JLR) of 2,99,664 units, marking a 9 per cent decline compared to Q1FY25. The global wholesales of the company's CV segment, including the Tata Daewoo range, stood at 87,569 units, reflecting a 6 per cent drop from the same period last year. Meanwhile, PV wholesales, including EVs, totaled 1,24,809 units in Q1 FY26.
GOCL: The Hinduja group firm has announced that the company Board of Directors has recommended a dividend of ₹10 per equity share of face value ₹2 each for the financial year ended March 31, 2024. This dividend proposal is subject to the approval of shareholders at the company's upcoming 64th Annual General Meeting (AGM), scheduled for next month.
Ceat: The Company has approved an investment of up to ₹355 Lakhs through subscription to the rights issue of equity shares of Tyresnmore Online Private Ltd. The investment will be made via subscription of up to 29,084 equity shares of face value ₹1 each, fully paid-up.
KPI Green Energy: The Ministry of Corporate Affairs has approved the incorporation of a special purpose vehicle (SPV) of the Company, named 'KPIN Clean Power Four LLP'. The SPV has been incorporated by the company with a total contribution of ₹99,000 by KPI and ₹1,000 by KPark Sunbeat Private Ltd., a wholly owned subsidiary of the Company. The SPV is yet to commence business operations and currently has no turnover. "The main objective of the SPV is to generate, develop, transform, distribute, transmit, sell, and supply power or electrical energy using wind energy, solar energy, or other renewable sources," the company stated in its exchange filing.
Synergy Green: Adani Wind has awarded Synergy Green Industries Ltd. a development order for 3.3 MW turbine parts. The development is expected to be completed in Q3 of FY26. Synergy Green is already supplying bearing housing castings for Adani's 5 MW turbine platform. With this latest order, the company's order book with Adani Wind is expected to grow significantly from ₹20 Crores in FY25 to an estimated ₹40 Crores in FY26, based on projected volumes.
Supreme Industries: The company has received a Letter of Acceptance (LOA) from Bharat Petroleum Corporation Ltd (BPCL) for the supply of 2,00,000 units of 10 kg composite LPG cylinders, awarded via a tender process. The total order value is estimated at approximately ₹54 crores. The contract will be valid for 6 months from the date of LOA, with a provision for extension or repetition for an additional 6 months at BPCL's sole discretion.
Tata Steel: The company reported crude steel production of 5.26 million tons in Q1FY26, slightly lower than the 5.44 million tons recorded in the previous quarter (Q4FY25). On a Y-o-Y basis as well, production declined marginally from 5.27 million tons in Q1FY25.
ZEE Entertainment Enterprises: The media company informed the exchanges that its shareholders approved the appointments of Divya Karani as an independent director and Saurav Adhikari as a non-executive director of the Company's Board. These appointments come at a time when the promoters of Zeel are planning to raise their stake in the company to 18.39 per cent via a preferential allotment of fully convertible warrants valued at ₹2,237.4 crore.
Dixon Technologies: The company has incorporated Lightanium Technologies Private Ltd. as a joint venture with Signify Innovations India Ltd. As per the exchange filing, Dixon Technologies has subscribed to 25,00,000 equity shares at face value of ₹10 each, amounting to a total investment of ₹2.5 crore.
5paisa: The company reported a consolidated income of ₹77.8 crore in Q1FY26, marking a 9 per cent growth Q-o-Q. The consolidated profit after tax (PAT) for the quarter stood at ₹11.5 crore, marking a 15 per cent increase compared to the previous quarter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
What's firing up Bharat Dynamics? 8 reasons behind MOFSL's positive view
MOFSL on Bharat Dynamics: Ammunition and missile systems manufacturers Bharat Dynamics Limited (BDL) shares were in focus on Thursday, July 10, 2025 after Motilal Oswal Financial Services (MOFSL) initiated coverage on the stock. On the bourses, however, Bharat Dynamics' share price fell 2.53 per cent to an intraday low of ₹1,934.80. Around 9:50 AM, the Bharat Dynamics share was trading 1.60 per cent lower at ₹1,953.30 per share, while the benchmark BSE Sensex was down 0.12 per cent at 83,434.31 levels. MOFSL today initiated coverage on Bharat Dynamics with a 'Neutral' rating and a target price of ₹1,900, indicating a downside of 4 per cent from current levels. 'The stock currently trades at 70x/52x/38x P/E on FY26/27/FY28 estimates. We initiate coverage on the stock with a 'Neutral' rating and a target price (TP) of ₹1,900 based on 42x September'27E P/E,' Teena Virmani and Prerit Jain, research analysts at MOFSL said, in a note dated July 10. Motilal Oswal analysts said that they like Bharat Dynamics' business model and strong growth potential but would prefer lower entry points given current valuations. They also flagged risks including any potential cut or reprioritisation in India's defence budget, contract cancellations or failures, changing procurement rules, and supply chain disruptions. Meanwhile, here are the 8 key reasons behind MOFSL's coverage initiation: Rising global spend boosts Indian defence According to MOFSL, NATO's recent commitment to raise defence spending to 5 per cent of GDP by CY35 has strengthened the outlook for global defence players, with indirect positive implications for India. This, analysts believe, could lead to India boosting its own defence budget and create new export opportunities for domestic players. Additionally, India's own emergency procurement drive and the Defence Acquisition Council's (DAC) recent approvals worth ₹1 trillion are expected to considerably expand the addressable market for companies like BDL. Positive industry tailwinds The company's estimated addressable market size is around ₹50,000 crore, driven by missile procurements across platforms including submarines (Project 75I), fighter jets (LCA Tejas Mk1A, Su-30MKI), and helicopters (LCH Prachand, ALH Dhruv). Continued demand for systems like QRSAM, MRSAM, NAG, and VSHORAD, alongside existing long-term contracts for high-value imports like S-400 and Barak-8, analysts highlighted, are expected to fuel growth. Export demand, especially for Akash missile systems, will also support order inflow. Emerging as a leading integrator of missile platforms MOFSL said Bharat Dynamics has transformed from a missile manufacturer into an end-to-end weapon systems integrator for the Army, Navy, and Air Force. It is expanding into drone-delivered payloads, guided bombs, warhead and engine manufacturing, and other segments such as mines and propellants. The company is actively exploring new partnerships with foreign original equipment manufacturers (OEMs) and continues to work closely with DRDO on a range of high-impact defence programs. Strong order book, easing supply chain issues to scale up revenue As of FY25-end, the missile maker's order book stood at ₹22,700 crore, registering a healthy compound annual growth rate (CAGR) of 27 per cent over FY20–24, driven by large deals related to Akash, Konkur, and exports. While supply chain bottlenecks due to the Russia-Ukraine conflict and regional geopolitical tensions in Israel had earlier impacted revenue conversion, MOFSL noted that these issues have begun to ease. With execution expected to normalise, the company is now projected to deliver a 35 per cent revenue CAGR over FY25–28. Focus on indigenisation Bharat Dynamics has been consistently localising its platforms, with import dependence falling majorly over the years. The company now achieves 80–90 per cent indigenisation on several missile systems, which boosts its ability to compete independently in domestic tenders. As a key development partner to DRDO for about 40 projects, BDL is well-positioned to capitalise on indigenous defence production as more projects move into the manufacturing phase. Continuous capacity growth, research efforts to minimise reliance on imports The company has expanded its in-house production capabilities with new facilities like the integrated Radio Frequency Seeker Unit at Kanchanbagh, aimed at producing and testing critical missile components. It is also increasing its capacity to manufacture next-gen SAMs, VSHORAD rockets, ATGM propellants, and more. R&D spending has risen sharply over the past two years, with ongoing efforts in both new product development and upgrading legacy systems to meet emerging operational requirements. Boosting exports BDL's export momentum has picked up sharply following government approvals for Akash system exports to nine countries. Export revenues rose to ₹1,200 crore in FY25 from ₹160 crore in FY24. The company's growing global portfolio includes Akash (SAM), Astra (Air-to-Air), Helina (Air-to-Surface), anti-airfield weapons, various torpedoes, and anti-tank missiles such as Konkurs-M and Milan-2T. Lightweight torpedoes have already been exported, and other products are seeing increasing interest globally. Strong financial outlook MOFSL projects a 35 per cent revenue CAGR and 51 per cent PAT CAGR for BDL over FY25–28, driven by improved execution and easing supply chain margins are expected to strengthen from 23.8 per cent in FY26 to 25.5 per cent by FY28, aided by indigenisation and lower provisioning. With a steady capex of ₹200–300 crore annually and efficient working capital management, the company's return on equity (RoE) and return on capital employed (RoCE) are projected to rise to 25.2 per cent and 25.6 per cent, respectively, by FY28.
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Thinking of investing in Anthem Biosciences IPO? Know key risks, strengths
Anthem Biosciences IPO: Contract research, development, and manufacturing organisation (CRDMO) Anthem Biosciences is set to launch its Initial Public Offering (IPO) on Monday, July 14, 2025. The public issue is entirely an Offer for Sale (OFS), with promoters and existing shareholders divesting up to 59.6 million equity shares, aggregating to approximately ₹3,395 crore. The public issue is entirely an Offer for Sale (OFS), with promoters and existing shareholders divesting up to 59.6 million equity shares, aggregating to approximately ₹3,395 crore. From the promoter group, Ganesh Sambasivam and K Ravindra Chandrappa are among those participating in the OFS. Viridity Tone LLP, Portsmouth Technologies LLC, and Malay J. Barua are among the shareholders divesting their stakes through the Anthem Biosciences IPO. Anthem Biosciences has set the price band for the IPO at ₹540 to ₹570 per share. The minimum application size has been set at 26 shares per lot. The issue will open for subscription on July 14 and remain available until July 16. The company's shares are tentatively scheduled to make their D-Street debut on July 21, 2025. It is worth noting that Anthem Biosciences will not receive any proceeds from the IPO. All the funds raised will go directly to the selling shareholders, after accounting for offer-related expenses and applicable taxes, which will be borne by the respective sellers. As investors await the opening of Anthem Biosciences IPO, here are the key strengths and risks outlined in its Red Herring Prospectus (RHP) that every investor should be aware of: Key strengths of Anthem Biosciences Strong global customer base with long-term relationships: As of March 31, 2025, Anthem Biosciences had more than 550 customers across both its CRDMO and specialty ingredients businesses, spread over more than 44 countries, including the United States, European countries, and Japan. Many of these customers have long-standing relationships with the company. According to the F&S Report, Anthem Biosciences has the highest number of customers among its assessed Indian peers as of March 2025. Market-leading fermentation capacity: The company has the largest fermentation capacity among Indian CRDMO companies, with a 142 kL capacity as of March 31, 2025. Following the completion of its expansion activities by the first half of Fiscal 2026, Anthem Biosciences' fermentation capacity is expected to reach 182 kL—more than six times the fermentation capacity of the second-largest assessed player in the industry, according to the F&S Report. Diversified specialty ingredients portfolio: Anthem Biosciences also maintains a wide specialty ingredients portfolio and is well-positioned to capitalise on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products, probiotics, enzymes, nutritional actives, vitamin analogues, and biosimilars. Focused business model for emerging pharma and biotech players: According to the F&S Report, while large multinational pharmaceutical companies currently dominate the global pharmaceuticals market, there is a growing prominence of small pharmaceutical and biotech companies, reflecting a broader shift in the pharmaceutical industry towards novel therapies and innovation-driven growth. Anthem Biosciences has a differentiated business model catering to the needs of small pharmaceutical and emerging biotech companies, from discovery to commercial manufacturing. Comprehensive end-to-end service capabilities: Anthem Biosciences offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development, and manufacturing) for both small molecules and biologics and is the fastest-growing Indian CRDMO. Key risks of Anthem Biosciences High dependence on CRDMO services: Anthem Biosciences' business depends on the demand for its contract research, development and manufacturing organisation (CRDMO) services, which contributed to 81.65 per cent of its revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they operate may have a material adverse effect on the company's business. Dependence on DavosPharma for US market presence: Anthem Biosciences is dependent on its arrangements with DavosPharma, the affiliate of one of its shareholders and also a selling shareholder, for its business and marketing activities in the United States. Reliance on the success of specific molecules: The company's financial performance is dependent on the success of the molecules it manufactures, and its revenue from operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failure of a Phase III molecule and the withdrawal of a commercialised molecule. Accordingly, any unfavorable developments affecting these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of commercialised molecules, may have an adverse impact on Anthem Biosciences' business, financial condition, results of operations, and prospects. Risks associated with project failures: Developmental and commercial manufacturing contributed to 70.78 per cent of Anthem Biosciences' revenue from operations and 71.90 per cent of its total number of projects in Fiscal 2025. The company's business may be adversely affected by a failure in early-phase developmental projects or a failure to develop or manufacture commercially viable drugs, including for reasons that are not within Anthem Biosciences' control.
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Nissan suspends US production of three vehicle models sold in Canada
Nissan said its top-selling vehicles in Canada, such as the Versa, Sentra and Rogue, were all sourced from either Mexico or Japan, accounting for 80 per cent of its Canadian sales Reuters TOKYO Nissan Motor has suspended US production of three vehicle models for Canada amid mutual tariffs imposed by the US and Canada on auto imports, the automaker said. It has halted production of Pathfinder and Murano SUVs and Frontier pickup trucks, the Japanese automaker said in a statement late on Wednesday, without saying when the suspension went into effect or how long it expected it to stay in place. "This is a short-term and temporary measure, and we remain hopeful that ongoing discussions between the US and Canadian governments will lead to a successful agreement in the near future," Nissan said in a statement. Nissan said its top-selling vehicles in Canada, such as the Versa, Sentra and Rogue, were all sourced from either Mexico or Japan, with production from those two countries accounting for 80 per cent of its Canadian sales. Nissan assembles the Pathfinder and Murano in Tennessee and the Frontier in Mississippi. The Trump administration imposed 25 per cent additional tariffs on auto imports in April, prompting Canada to implement retaliatory tariffs. Mazda Motor also halted Canada-bound production at its Alabama plant while boosting production for the US market, the company said in May. While Canada is a relatively small market for Nissan, the suspension underscores the difficulty facing global automakers from the tariffs. The levies have also added to a deepening crisis at Nissan, which has been badly hit by deteriorating sales and an ageing vehicle lineup. It reported a $4.5 billion net loss in the financial year that ended in March and has declined to disclose a forecast for the current financial year, when it also faces some 700 billion yen ($4.79 billion) in debt coming due. Its debt ratings have been cut to "junk" by all three major credit-rating firms. Reuters reported last month that the automaker has asked some suppliers to allow it to delay payments to free up short-term funds, in a sign of its scramble to boost cash. Nissan does not have factories in Canada. In the last financial year it sold around 104,000 vehicles there, less than half of what it sold in Mexico and a little more than 10 per cent of what it sold in the United States. Overall, Canada accounted for just 3 per cent of Nissan's global sales in the last financial year.
